Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2016
At a glance
- Drugs Vildagliptin/metformin (Primary) ; Metformin
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms VAAST
- 10 Jun 2017 Biomarkers information updated
- 18 Apr 2016 Status changed from recruiting to completed.
- 29 Jul 2013 Planned End Date changed from 1 Feb 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.